OUP user menu

Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies
Quality Control Guidelines, Comments, and Recommendations for Testing in Other Autoimmune Diseases

Judy Savige FRACP, FRCPA, PhD, Wayne Dimech FAIMS, Marvin Fritzler MD, James Goeken MD, E. Chris Hagen MD, J. Charles Jennette MD, Rob McEvoy PhD, Charles Pusey MD, Wendy Pollock, Michelle Trevisin, Allan Wiik MD, Richard Wong FRACP, FRCPA
DOI: http://dx.doi.org/10.1309/WAEPADW0K4LPUHFN 312-318 First published online: 1 September 2003


Antineutrophil cytoplasmic antibody (ANCA) tests are used to diagnose and monitor inflammatory activity in Wegener granulomatosis, microscopic polyangiitis and its renal-limited variant (pauciimmune crescentic glomerulonephritis), and Churg-Strauss syndrome. The International Consensus Statement on testing and reporting of ANCA states that ANCA are demonstrated most readily in these conditions by using a combination of indirect immunofluorescence (IIF) of normal peripheral blood neutrophils and enzyme-linked immunosorbent assays (ELISAs) that detect ANCA specific for proteinase 3 or myeloperoxidase. The group that produced the International Consensus Statement has developed guidelines for the corresponding quality control activities, examples of comments for various IIF patterns and ELISA results, and recommendations for ANCA testing when inflammatory bowel disease and other nonvasculitic ANCA-associated autoimmune diseases are suspected.

Key Words:
  • Antineutrophil cytoplasmic antibodies
  • Churg-Strauss syndrome
  • Microscopic polyangiitis
  • Quality control
  • Renal-limited vasculitis
  • Vasculitis
  • Wegener granulomatosis